Since the Drug Marketing Authorization Holder (MAH) system was rolled out in 10 provinces in China under a trial program last year, coupled with support from local financial subsidies, China’s FDA had received 381 MAH applications by June this year, including some for global novel drugs.
Given the positive feedback, the new system is now expected to be promoted nationwide, and the details of implementation are...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?